ArticlePediatric nephrology (Berlin, Germany)2021

Correction to: The long-acting C5 inhibitor, ravulizumab, is efficacious and safe in pediatric patients with atypical hemolytic uremic syndrome previously treated with eculizumab.

Kazuki Tanaka et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.